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An organ-based lung cancer registry is currently maintained by the Japan Joint Committee
of Lung Cancer Registry; this registry contributes to the development of lung cancer
treatments and provides TNM classiﬁcation data. In Japan, the overall 5-year survival rate
has improved over time to 52% in 2004; the corresponding rates for each pathologic stage
have also improved. Previously, separate registries were maintained for surgical and non-
biased cases, whereas a prospective registry for non-surgical cases was added in 2012, and
a follow-up examination of those data will be conducted in 2016. In addition, a registry of
surgical cases from 2010 will be constructed in 2016. The information provided by these
registries should better reveal the status of lung cancer patients in Japan.
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Two types of Japanese cancer registries exist: a “population-
based” registry that depends on information provided by
hospitals and an “organ-based” cancer registry that is main-
tained by academic organizations. The population-basedTable 2 – Perioperative complications and deaths among surgi
1994
n (%)
Total 7393
Complications (Grade Z3)
Yes
No
Missing
Deaths
Operative (r30 days) 101 (1.4)
Hospital (430 days) 122 (1.7)
Lung cancer 2635 (35.6)
Other cancer 124 (1.7)
Other disease 461 (6.2)
Unknown 272 (1.9)
Missing
Table 1 – Findings from the registries of surgical cases.
Year
1994
n (%)
Total 7408
No. institute 303
Age (years)
Mean 64.5
o50 615 (8.3)
50–60 1334 (18.0)
60–70 2984 (40.4)
70–80 2222 (30.1)
480 233 (3.1)
Missing 5 (0.1)
Gender
Male 5154 (69.7)
Female 2197 (29.7)
Missing 42 (0.6)
Tumor size (cm)
o1.0 249 (3.4)
1.0–1.5 526 (7.1)
1.5–2.0 942 (12.7)
2.0–2.5 952 (12.9)
2.5–3.0 926 (12.5)
43.0 3745 (50.6)
Missing 53 (0.7)
Tumor histology
Adenocarcinoma 4116 (55.7)
Squamous cell carcinoma 2441 (33.0)
Large cell carcinoma 266 (3.6)
Adeno-squamous cell carcinoma 185 (2.5)
Small cell carcinoma 248 (3.4)
Others 129 (0.8)
Missing 8 (0.1)
c-Stage (Ver. 6)
Ia, Ib 4354 (58.9)
p-Stage (Ver. 6)
Ia, Ib 3715 (30.3)cancer registry produces domestic reports, including the
numbers of patients, survival rates, and other information,
that demonstrate the level of medical care provided in Japan.
In contrast, the organ-based cancer registry deals with aca-
demic issues.
Regarding lung cancer, the Japan Joint Committee of Lung
Cancer Registry (JJCLCR) has established an organ-basedcal cases.
1999 2004
n (%) n (%)
13344 11663
1422 (10.7) 523 (4.5)
11913 (89.3) 11140 (95.5)
9 (0.1) 0 (0)
123 (0.9) 48 (0.4)
146 (1.1) 46 (0.4)
3397 (25.4) 2459 (21.1)
183 (1.4) 215 (1.8)
680 (5.1) 570 (4.9)
148 (2.0) 87 (0.7)
21 (0.3) 0 (0.0)
1999 2004
n (%) n (%)
13344 11663
386 253
65.8 66.7
877 (6.6) 596 (5.1)
2312 (17.3) 2065 (17.7)
4610 (34.5) 3712 (31.8)
4823 (36.1) 4584 (39.3)
602 (4.5) 705 (6.0)
223 (1.6) 1 (0.0)
8878 (66.5) 7369 (63.2)
4344 (32.6) 4264 (36.8)
122 (0.9) 0 (0.0)
746 (5.6) 1057 (9.1)
1227 (9.2) 1459 (12.5)
1972 (14.8) 1787 (15.3)
1824 (14.3) 1730 (14.8)
1527 (11.4) 1336 (11.5)
5768 (43.5) 3294 (36.7)
240 (1.8) 0 (0.0)
8239 (61.7) 7921 (67.9)
3700 (27.7) 2600 (22.3)
474 (3.6) 387 (3.2)
204 (1.6) 225 (1.9)
390 (2.9) 243 (2.1)
265 (1.9) 287 (2.5)
69 (0.5) 0 (0.0)
9181 (68.8) 9083 (77.9)
7810 (48.5) 7048 (56.5)
Table 3 – Changes in surgical case survival rates.
1994 1999 2004
Ver. 6 Ver. 6 Ver. 6 Ver. 7
n (%) 5-YSR (%) n (%) 5-YSR (%) n (%) 5-YSR (%) n (%) 5-YSR (%)
Total 7238 52 13344 62 11663 70 11663 70
c-Stage
IA 2618 30.2 72 5939 45.0 77 6295 54.0 82 6295 54.0 82
IB 1646 23.0 50 3242 24.5 60 2788 23.9 63 2339 20.1 66
IIA 169 2.4 48 226 1.7 54 203 1.7 55 819 7.0 55
IIB 793 11.1 40 1304 9.9 44 899 7.7 49 648 5.6 46
IIIA 1385 19.3 35 1723 13.0 38 940 8.1 43 1216 10.4 43
IIIB 395 5.5 28 567 4.3 34 407 3.5 42 90 0.1 40
IV 162 2.3 20 211 1.6 27 131 1.1 29 256 2.2 31
Missing 70 132 0 0
Total 7168 13212 11663 11663
p-Stage
IA 2142 30.4 79 5007 38.2 83 5611 48.1 86 4978 42.7 87
IB 1488 21.1 60 2803 21.4 66 2398 20.4 69 2552 21.9 74
IIA 261 3.7 59 400 3.0 60 336 2.9 61 941 8.1 62
IIB 785 11.1 42 1388 10.6 47 977 8.4 52 848 7.3 60
IIIA 1337 19.0 28 1944 14.8 32 1354 11.6 41 1804 15.5 50
IIIB 759 10.8 20 1179 9.0 30 799 6.9 37 106 0.9 38
IV 275 3.9 19 397 3.0 23 188 1.6 28 434 3.7 38
Missing 191 226 0 0
Total 7047 13118 11663 11663
5-YSR, 5-year survival rate.
Table 4 – Prognostic analyses of non-biased and nonsurgical cases according to the histological type among patients
treated in 2002.
Non-small cell lung cancer Small cell lung cancer
Non-biased No surgery Non-biased No surgery
n (%) 5-YSR (%) n (%) 5-YSR (%) n (%) 5-YSR (%) n (%) 5-YSR (%)
Total 12,993 (100) 47 4452 (100) 5 1323 (100) 15 1088 (100) 5
c-Stage
IA 4020 (31.0) 80 150 (3.5) 41 96 (7.3) 53 10 (0.9) 32
IB 2113 (16.4) 57 179 (4.0) 16 57 (4.3) 39 12 (1.1) 18
IIA 184 (1.4) 49 34 (0.8) 11 20 (1.5) 32 11 (1.0) 30
IIB 860 (6.6) 42 156 (3.5) 16 40 (3.0) 30 20 (1.8) 16
IIIA 1441 (11.1) 31 519 (11.7) 7 211 (16.7) 17 126 (11.5) 17
IIIB 1714 (13.2) 17 1270 (25.3) 9 356 (26.9) 12 356 (32.7) 16
IV 2447 (18.5) 6 2144 (48.1) 4 533 (40.3) 4 533 (49.0) 5
5-YSR, 5-year survival rate.
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organizations: the Japan Lung Cancer Society, Japanese Asso-
ciation for Chest Surgery, Japanese Respiratory Society, and
Japanese Society for Respiratory Endoscopy. This registry
includes the characteristics of lung cancer patients nation-
wide and aims to contribute to treatment development and to
offer data to support the TNM classiﬁcation organized by the
Union for International Cancer Control, American Joint Com-
mittee on Cancer, and International Association for the Study
of Lung Cancer [1]. Of the 2 different types of Japanese lung
cancer registries, the population-based registry depends on
the conventional TNM classiﬁcation system, whereas theorgan-based registry collects new information intended to
validate the new TNM staging program. In this review, we
analyzed the prognoses of lung cancer patients in Japan
according to data from the JJCLCR.2. Materials and methods
Registries of surgical cases performed in 1994, 1999, and 2004
were added to the registry in 1999, 2004, and 2010, respec-
tively, along with patient background information [2–4]. In
addition, surgical and non-surgical (non-biased) cases treated
r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 3 1 7 – 3 2 1320in 2002 were registered and analyzed in 2009 [5]. Using data
from those registries, we assessed the trend of lung cancer
patient prognoses in Japan.3. Results
The ﬁndings from the registries of surgical cases in 1994,
1999, and 2004 are summarized in Table 1. The mean patient
age and the proportions of older patients, female patients,
small-sized tumors, adenocarcinoma, and stage I tumors
have increased over time. The perioperative complications
and deaths are summarized in Table 2. The rates of perio-
perative and hospital deaths as well as the rates of complica-
tions have decreased over time. In 2004, the rate of grade Z30
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Fig. 1 – Survival curves for surgical patients in 2004. (a) The
survival rates according to pathological stage (Ver. 7) were
87% among stage IA patients (n¼4978), 74% among stage IB
patients (n¼2552), 62% among stage IIA patients (n¼941),
60% among stage IIB patients (n¼848), 50% among stage IIIA
patients (n¼1804), 38% among stage IIIB patients (n¼106),
and 38% among stage IV patients (n¼434). (b) The survival
rates of patients with small cell lung cancer according to the
pathological stage (Ver. 7) were 72% among stage IA patients
(n¼93), 61% among stage IB patients (n¼51), 45% among
stage IIA patients (n¼27), 40% among stage IIB patients
(n¼17), 23% among stage IIIA patients (n¼45), and 9%
among stage IV patients (n¼9); all stage IIIB patients (n¼1)
were censored.complications was 4.5%, whereas the rates of perioperative
and hospital deaths were 4.5% and 0.4%, respectively.
Changes in the survival rate are summarized in Table 3.
The overall 5-year survival rate (5-YSR) improved over time
and was 52% for surgical patients in 2004. In addition, the
5-YSR for each pathologic stage also improved over time. The
survival curves of surgical patients at each pathological stage
in 2004 are shown in Fig. 1a, whereas those of patients with
small cell lung cancer are shown in Fig. 1b.
The surgical and non-surgical (non-biased) cases treated
in 2002 were registered and analyzed in 2009. The results of
the prognostic analyses are summarized in Table 4, which
shows that the overall 5-YSR for non-small cell lung cancer
patients was 47% and that for small cell lung cancer patients0
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Fig. 2 – Survival curves for non-surgical patients in 2002. (a)
The survival rates for patients with non-small cell lung
cancer according to clinical stage (Ver. 6) were 41% for stage
IA (n¼159), 16% for stage IB (n¼179), 11% for stage IIA
(n¼34), 16% for stage IIB (n¼156), 7% for stage IIIA (n¼519),
9% for stage IIIB (n¼1270), and 4% for stage IV (n¼2144). The
survival rate for all non-small cell lung cancer patients was
5% (n¼4452). (b) The survival rates for patients with small
cell lung cancer according to clinical stage (Ver. 6) were 32%
for stage IA (n¼10), 18% for stage IB (n¼12), 30% for stage IIA
(n¼11), 16% for stage IIB (n¼20), 17% for stage IIIA (n¼126),
16% for stage IIIB (n¼356), and 5% for stage IV (n¼533).
The survival rate for all small cell lung cancer patients was
5% (n¼1088).
r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 3 1 7 – 3 2 1 321was 15%. Additionally, the extracted results with respect to
the survival of non-surgical cases are shown in Fig. 2.4. Discussion
Previously, registries were constructed for surgical and non-
biased cases; however, a prospective registry for non-surgical
cases was constructed with 410,000 registered cases in 2012,
and a follow-up examination of those data is scheduled to be
performed in 2016. In this registry, the status of epidermal
growth factor receptor mutations and ﬂuorodeoxyglucose-
positron emission tomography examination ﬁndings will also
be investigated. Additionally, a registry for surgical cases
treated in 2010 will be constructed in 2016.5. Conclusion
Data from the JJCLCR revealed that the overall 5-YSR for
surgical cases has improved over time to reach 52% in 2004.
Additionally, in 2002, among non-biased patients, the overall
5-YSR for non-small cell lung cancer patients was 47% and
that for small cell lung cancer patients was 15%. Future
registries will continue to reveal the status of lung cancer
patients in Japan.Conﬂict of interest
The author has no conﬂicts of interest.
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